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Abstract
Introduction Several cardiovascular agents, such as diuretics
and β-blockers, can negatively affect sexual function, leading
to noncompliance with therapy. Others such as angiotensin II
receptor blockers (ARBs) can improve patients’ sexual
function.
Aims We aimed to gain insight into cardiologists’ knowledge
about the effects of cardiovascular drugs on sexual function
and whether they take this knowledge into account when
prescribing drugs.
Methods An anonymous questionnaire was mailed to 980
members of the Netherlands Society of Cardiologists
(cardiologists and residents in training).
Results Almost 54 % of Dutch cardiologists responded; 414
questionnaires were analysed. Forty-five percent of cardiolo-
gists were aware that diuretics can negatively affect sexual
function, 93.1 % knew about the negative effects β-blockers
can have, but only 9.2 % were aware that ARBs can have
positive effects on sexual health. Almost half of respondents
(48.2%) stated they changemedication regularly in an attempt
to improve sexual function. Experienced cardiologists said they
do this significantly more often than less experienced ones.
Conclusions Cardiologists’ knowledge about the effects of
cardiovascular drugs on sexual health appears to be insuffi-
cient. Sexual dysfunction is not routinely taken into account
when cardiologists prescribe drugs.
Keywords Sexualdysfunction .Adrenergicbeta antagonists .
Angiotensin-converting enzyme inhibitors . Angiotensine
receptor antagonists . Diuretics . Calcium channel blockers .
Hydroxymethylglutaryl-CoA reductase inhibitors
Introduction
Since the late 1980s a rapid increase in the number of pre-
scriptions for the treatment and prevention of cardiovascular
disease (CVD) began.
The class of antihypertensive agents is the second most
commonly prescribed class of medication, exceeded only by
antidepressants [1]. In this time of high life expectancies, this
therapy will be received during a substantial part of patients’
lives [2]. The side effects induced by cardiovascular drugs are
strongly associated with an impaired quality of life [3], affect-
ing both patients and their partners [4]. Some classes of
cardiovascular drugs have been described to cause sexual
dysfunction. Diuretics and β-blockers can give rise to a de-
crease in libido, difficulty attaining or maintaining an erection
and ejaculation problems [5–7]. However, recent literature
describes beneficial effects on sexual health for third-
generation β-blockers [8], angiotensin II receptor blockers
(ARBs) [9–12] and statins [13]. Existing data of experimental,
observational and clinical studies consistently point towards
similar effects of antihypertensive drugs on male and female
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sexual function [14–16]. As many as 70 % of hypertensive
patients who experience side effects are non-compliant with
their antihypertensive medication and have a 40 %–60 %
higher rate of therapy discontinuation, compared with patients
whose quality of life is unaffected [17, 18]. Since non-
adherence with antihypertensive therapy can be life threaten-
ing, it is of great importance for cardiologists to be aware of
the side effects that may be caused by the drugs they prescribe,
including effects on patients’ sexual function. Of course,
cardiovascular drugs that improve symptoms and survival
should not be withheld due to concerns about their potential
impact on sexual function [19]. But whenever possible, mul-
tiple alternative options are available in order to provide
patient-centred care. These options are described in part II of
this article, which will be published in a later issue of this
journal. Information about cardiologists’ practice patterns
concerning switches in medication, in order to improve pa-
tients’ sexual function, is not yet available. Neither is it known
whether cardiologists are aware of the different effects of
cardiac drugs on sexual function. However, cardiologists will
only be able to provide medicinal therapy with an optimum
balance between efficacy and quality of life and to provide
patients with sufficient information regarding the prescribed
therapy if they have knowledge about these effects.
A recent report from our group revealed that Dutch cardiol-
ogists did not routinely discuss sexual function and a consid-
erable number (41.9 %) of the respondents indicated a need for
training to increase their knowledge to be able to discuss sexual
matters with patients [20]. Accordingly, we hypothesised that
information about the several effects of cardiovascular agents
on sexual function has not yet permeated the cardiology prac-
tice. Therefore, aim of this study was to evaluate to what extent
cardiologists are aware of the potential negative, neutral or
beneficial effects that cardiovascular drugs can have on sexual
function and whether this knowledge is actively used in patient
care. We made use of additional data obtained during the
National survey among cardiologists assessing their awareness,
knowledge and practice patterns regarding sexual dysfunction
in cardiac patients. Results of this survey, in combination with
the review (part II), will provide cardiologists and residents in
cardiology with the necessary information to be able to provide
holistic healthcare.
Methods
Study design and sample
A national cross-sectional questionnaire survey was set
among all active Dutch cardiologists and residents in cardiol-
ogy (1054) who were members of the Netherlands Society of
Cardiology (NVVC) in the autumn of 2011. However, some
addresses from the society were out of date, leading to a total
of 980 questionnaires which could be sent to the work ad-
dresses of NVVC members.
Survey and procedure
The study methodology was identical to a previously reported
assessment of Dutch cardiologists, evaluating their inquiry
into patients’ sexual function [20]. The questionnaire was
designed by the authors, based on a review of the literature.
A multidisciplinary expert panel, with experience in develop-
ing surveys, checked the questionnaire for comprehensiveness
and quality. The survey was pilot tested with 40 anonymous
pilot questionnaires, which were distributed to cardiologists
and residents in cardiology from the Leiden University Med-
ical Centre. Of the pilot questionnaires, 23 were completed and
returned (response rate 57.5 %). To improve the suitability and
comprehensiveness of the questionnaire, it was adjusted
according to the remarksmade by the responding cardiologists.
The questionnaire comprised 31 questions focusing on current
practice in addressing sexual health and knowledge about
(side) effects of the eight main classes of cardiovascular drugs.
Questionnaires were accompanied by a letter explaining the
nature, scope, objectives and contents of the questionnaire and
total anonymity was ensured. A free post return envelope was
added, as well as an opt-out possibility. Cardiologists not
interested in participation could answer a question regarding
the reason(s) not to participate and return the questionnaire
empty. Reminder letters were sent to non-respondents 2, 5 and
7 months after the initial mailing.
Results about cardiologists daily practice patterns regarding
assessment of sexual function were published separately [20].
Data analysis
Means of numerical demographic values and answers to the
questions were analysed with frequencies. Bivariate associa-
tions between demographic information and the categorical
data were calculated using the Pearson chi-square procedure,
for ordinal variables Armitages’ trend test was used. Associa-
tions between numerical data and demographics of the respon-
dents were analysed with the independent sample t-tests. Two-
sided P values<0.05 were considered statistically significant.
Some questions with more than one possible answer and with
open answers were grouped together for analysis. Data were
analysed by SPSS release 20 (SPSS Inc., Chicago, IL, USA).
Results
Demographics
Of the 980 eligible participants, 528 surveys were returned,
yielding an unweighted response rate of 53.9 %. Seven
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participants were eliminated because they were not participat-
ing in a clinical setting or because they were physician assis-
tants. A total of 98 questionnaires were eliminated because
they were empty or incomplete for more than 60 % and 16
because they lacked answers to the most important questions.
Reasons mentioned for the inability to fill in the questionnaire
(n =114) were: not interested (n =4), no time (n =2), or not
enough experience in the field (n =2). Others indicated they
were only working with specific patient groups such as chil-
dren or pregnant women and therefore were not able to fill in
the questionnaire (n =5). However, most cardiologists who
indicated unwilling to participate, gave no reason for this
(n =101). In total 78.4 % of the returned surveys were analysed
(n =414).Mean age of the respondents was 45.5 years (± 9.60),
76.0 % were male, 80.9 % were cardiologists and 19.1 % were
residents. Female respondents were significantly younger than
male respondents (mean 42.3±8.37 and 46.6±9.75, respec-
tively; p <0.001), consequently more female respondents were
residents (p <0.001). Demographic characteristics of non-
respondents were not available for analysis due to the anony-
mous design of the survey. The personal and practice charac-
teristics of respondents are summarised in Table 1.
Knowledge about sexual side effects
More than one fourth (27.5 %) of respondents stated they have
‘not much’ of the knowledge necessary to discuss sexual
function with patients, 2.0 % said they have no knowledge
about this at all. The majority of cardiologists reported having
‘some’ (65.1 %) and only 5.4 % ‘a lot’ of the necessary
knowledge to discuss sexual problems with patients. Respon-
dents were asked to note which effect on sexual function they
thought was caused by each class of cardiovascular drugs
(positive, neutral or negative). For β-blockers, 93.1 % of the
cardiologists believed these to have negative effects on sexual
function. Significantly more female physicians thought β-
blockers have a positive effect on sexual function compared
with male physicians (9.1 % and 1.6 %, respectively; p <
0.001). Regarding diuretics, respondents gave more diverse
answers: 57.7 % said they have a neutral effect and 40.5 %
knew they have a negative effect on sexual function. The
majority (64 %) indicated ARBs to have a neutral effect on
sexual function, only 9.2 % knew this class can have benefi-
cial effects on sexual function. Cardiologists’ answers regard-
ing the presumed effects of cardiovascular drugs on sexual
function are illustrated in Fig. 1. No significant differences
between male and female physicians were seen.
Counselling about sexual side effects
The majority of the responding cardiologists (76.6 %) stated
to counsel their patients regularly or often about sexual side
effects of cardiovascular drugs. Fifteen percent said they
inquired about sexual problems when a patient had recently
started using cardiac medication and 74.4 % when a patient
recently started using a β-blocker. On the contrary, only
19.3 % of respondents inquired regularly or often about
PDE-5 inhibitor use, while 43.6 % said they informed patients
Table 1 Respondent characteristics (n =414)
Age (years) n (%)
≤ 45 208 (50.2)







Type of clinic/practice n* (%)
Tertiary referral centre (or university hospital) 90 (21.8)
District general teaching hospital 174 (42.2)
District general hospital 148 (35.9)
Time of practice in cardiology n* (%)
0–11 month 18 (4.3)
1–2 years 30 (7.2)
3–5 years 80 (19.3)
6–10 years 106 (25.6)
11–15 years 49 (11.8)
15 years or more 131 (31.6)
* n differs because the questions were not answered consistently, some
were skipped or forgotten
Fig. 1 Effects of eight classes of cardiovascular medication on the sexual
function as presumed by the responding cardiologists, shown in percent-
ages. Based on answers of at least 400 cardiologists (in training) per
category
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about the possibility to use a PDE-5 inhibitor after a myocar-
dial infarction (MI) or in patients with heart failure. Further-
more, 48.2 % of respondents said they changed medications
regularly or often in an attempt to improve sexual function
(Table 2). Significant differences were seen regarding this
statement; cardiologists stated to switch significantly more
often than residents (p <0.001). Finally, the more knowledge
about sexual function cardiologists thought they had, the more
often they changed medication in an attempt to improve
sexual function (linear-by-linear association, p =0.002) and
the more often they counselled patients about effects and use
of erection potentiating medication (linear-by-linear associa-
tion, p =0.032 and p <0.001, respectively).
Discussion
This study indicates cardiologists are not fully aware of the
effects cardiovascular drugs can have on sexual function.
Although the majority of responding cardiologists stated they
informed patients about sexual side effects from the medica-
tion they prescribe, their knowledge of these effects seems
incomplete. Most cardiologists designated negative effects on
sexual function to β-blockers, although third-generation β-1
blockers have been shown to have beneficial effects on sexual
function. Furthermore, the lion’s share of respondents thought
no effects on sexual function were to be expected from most
other classes of cardiovascular drugs, underestimating that
most classes of cardiovascular drugs either have a beneficial
or a negative effect on sexual function. Interestingly, more
experience as a cardiologist was positively associated with
informing about sexual function and counselling about side
effects, suggesting that more education about sexual health in
cardiologists’ training could improve awareness and thus
quality of patient care on this point.
This was the first survey among cardiologists assessing
their knowledge about (side) effects of cardiovascular agents
and their practice patterns regarding switching of medication
in order to resolve or avoid sexual dysfunction. The findings
should be considered in the light of potential study limitations.
First, the self-reported character may have led to response and
selection bias although the response rate was sufficient and the
demographics found were comparable with the national
figures. Second, we made use of a non-validated question-
naire, since validated questionnaires about this subject are not
available. Third, the questionnaire was designed to obtain
information about cardiologists’ knowledge and practice pat-
tern concerning both male and female sexual function. Most
trials investigating effects of cardiovascular drugs on sexual
function are specifically designed to measure effects on erec-
tile function since this is a common problem which is easy to
measure with one of the available validated questionnaires
[21]. And, because erectile dysfunction has been shown to be
a sentinel marker for risk of cardiovascular disease [22] it has
received full attention in the past years, while very little
attention was paid to female sexual dysfunction. Respondents
may therefore answered the questionnaire with erectile dys-
function in mind, this may have led to an upward distortion of
the results.
Our data indicate that there is room for improvement
regarding cardiologists’ knowledge about the sexual (side)
effects of cardiovascular drugs. To improve compliance of
therapy in cardiology, patients should be properly informed
about side effects that can be expected from a drug and equally
important, patients should have the possibility to discuss a
switch in medication with their physician when sexual dys-
function occurs. Large clinical trials about the effects of
switching are lacking and should be conducted in the near
future. However, available data from observational studies
and clinical trials point consistently towards significant bene-
fits for sexual function when prior antihypertensive therapy is
switched to either nebivolol or an ARB (Part II and references
5 and 23) as significant improvements were observed in
orgasmic function and intercourse satisfaction, along with
benefits in sexual desire and frequency of sexual intercourse
[11, 23]. From an different angle, the American Heart Guide-
line [24] states that sexual dysfunction has not been associated
with the use of ACE inhibitors, ARBs and calcium channel
blockers. Cardiologists should be aware that these drug clas-
ses can be prescribed safely.
Obviously, patients’ health and cardiac condition take pre-
cedence above sexual function. In young patients with chronic
Table 2 Counselling and informing patients with erectile dysfunction
How often do you counsel patients regarding erectile
function (EF) after MI or with heart failure about:
Never n (%) Seldom n (%) Regularly n (%) Often n (%) n* (total)
Use of nitrates with pain 42 (10.4) 112 (27.8) 145 (36.0) 104 (25.8) 403
Effects of medication on EF 15 (3.7) 80 (19.8) 197 (47.5) 110 (27.2) 404
Use of PDE5 inhibitors 27 (6.7) 202 (49.8) 154 (37.9) 23 (5.7) 406
How often do you: Never n (%) Seldom n (%) Regularly n (%) Often n (%) n* (total)
Inform about erection potentiating agents 93 (23.6) 234 (57.6) 59 (14.5) 20 (4.9) 406
Change medication to improve sexual function 17 (4.2) 193 (47.7) 176 (43.5) 19 (4.7) 405
* N differs because the questions were not answered consistently, some were skipped or forgotten.
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heart failure, for example, especially those awaiting heart
transplantation, the use of β-blockers is of the utmost impor-
tance to improve survival and should not be withheld in order
to preserve sexual function. In addition, without even taking
the comorbidities into account, heart failure itself often leads
to deterioration in the physical condition and to erectile dys-
function independent of the medication used [25]. Choices for
medicinal treatment should always be balanced between car-
diologists’ expert judgments and patients’ wishes. But while
guidelines highly recommend routine assessment of sexual
function before initiation of antihypertensive treatment [26],
our results showed that inquiry about sexual function is not yet
routine in cardiology practice. A significant number of Dutch
cardiologists lacked the knowledge to be able to provide
accurate information about the effects cardiovascular agents
can have on sexual function. Experience and sufficient self-
perceived knowledge about sexual health appeared to be
crucial factors for inquiring and dealing with medicinal effects
on sexual function. Therefore, education about these (side)
effects in cardiologists training could be useful to enable
cardiologists to deal with patients presenting with sexual
dysfunction during treatment with cardiovascular agents.
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